Merck

ESMO: Despite checkered past, Merck's Keytruda-Lenvima pairing looks to change practice in liver cancer subtype
Fierce Pharma
Sun, 09/15/24 - 06:30 pm
ESMO
Merck
Eisai
Keytruda
Lenvima
liver cancer
ESMO: Despite positive trial, Merck's Welireg still comes up short in overall survival
Fierce Pharma
Fri, 09/13/24 - 11:12 am
Merck
Welireg
renal cell carcinoma
Novartis
Afinitor
ESMO
clinical trials
Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data
Fierce Biotech
Mon, 09/9/24 - 11:30 am
Merck
Daiichi Sankyo
I-DXd
small cell lung cancer
clinical trials
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
BioPharma Dive
Sun, 09/8/24 - 11:32 pm
Summit Therapeutics
Merck
Keytruda
clinical trials
non-small cell lung cancer
Merck and EyeBio launch trial of Restoret for diabetic macular edema
Clinical Trials Arena
Thu, 09/5/24 - 11:33 am
Merck
EyeBio
diabetic macular edema
diabetes
Restoret
Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.
Pharma Voice
Thu, 09/5/24 - 11:29 am
Merck
media
communications
Regeneron joins Koneksa Parkinson's digital biomarker study
Pharmaphorum
Wed, 09/4/24 - 11:22 am
Regeneron
Koneska Health
digital biomarkers
Parkinson's Disease
Merck
Merck’s Keytruda flunks pivotal studies in early-stage lung and skin cancers
Fierce Pharma
Thu, 08/29/24 - 11:15 am
Merck
Keytruda
non-small cell lung cancer
clinical trials
cutaneous squamous cell carcinoma
First real-world data for rVSV-ZEBOV vaccine supports use for future Ebola outbreaks
Clinical Trials Arena
Tue, 08/27/24 - 11:38 am
Merck
vaccines
rVSV-ZEBOV
ebola virus
real world data
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Fierce Pharma
Fri, 08/23/24 - 10:55 am
FDA
stomach cancer
Bristol Myers Squibb
Opdivo
Yervoy
Merck
Keytruda
BeiGene
Tevimbra
First real-world analysis of Merck's Ebola vaccine reveals 84% efficacy during DRC outbreak
Fierce Pharma
Thu, 08/22/24 - 11:11 am
Merck
vaccines
ebola virus
IRA negotiations slash Medicare prices for Big Pharma blockbusters by up to 79%
Fierce Pharma
Thu, 08/15/24 - 11:55 am
Medicare
drug pricing
Inflation Reduction Act
JNJ
Xarelto
Imbruvica
Stelara
Bristol Myers Squibb
Eliquis
Eli Lilly
Jardiance
Merck
Januvia
Amgen
Enbrel
AstraZeneca
Farxiga
Novo Nordisk
Fiasp
Novartis
Entresto
Merck bets $700M on an antibody drug’s potential in immune diseases
BioPharma Dive
Fri, 08/9/24 - 11:57 am
Merck
autoimmune disease
Curon Biopharmaceutical
China
bispecific antibodies
Pharma execs react to final drug price negotiations with Medicare
Pharma Voice
Fri, 08/9/24 - 11:21 am
Medicare
drug pricing
Inflation Reduction Act
Bristol Myers Squibb
Eli Lilly
JNJ
Bayer
Merck
AstraZeneca
Novartis
Amgen
AbbVie
Novo Nordisk
Gardasil Chinese Distribution Issue Still a Mystery to Analysts
BioSpace
Thu, 08/8/24 - 11:12 am
Merck
Gardasil
vaccines
HPV
China
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
Pharma Voice
Thu, 08/8/24 - 11:07 am
Big Pharma
JNJ
AbbVie
Pfizer
Roche
Eli Lilly
Novo Nordisk
Merck
Merck stops phase 3 TIGIT trial in lung cancer for futility—and sees immune side effects again
Fierce Biotech
Thu, 08/8/24 - 11:04 am
Merck
Tigit
lung cancer
clinical trials
MK-7684A
Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo
Fierce Biotech
Tue, 08/6/24 - 11:20 am
Merck
Harpoon Therapeutics
Daiichi Sankyo
small cell lung cancer
3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field
Fierce Pharma
Mon, 08/5/24 - 11:41 am
Merck
AstraZeneca
Gilead Sciences
clinical trials
antibody-drug conjugates
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
Clinical Trials Arena
Fri, 08/2/24 - 11:50 am
Daiichi Sankyo
Merck
clinical trials
I-DXd
small cell lung cancer

Pages